All 48 GLP-1 providers, side-by-side

Pros

• +4.5 stars across 3,777 verified Trustpilot reviews — 77% give 5 stars. Replies to 99% of negative reviews. The strongest customer-experience signal of any provider in our table.
• +Doctors are board-certified obesity medicine specialists — not general practitioners. Specialized training in weight and metabolism.
• +Quarterly blood panels (metabolic, lipid, A1C) are included in the monthly price. Most competitors don't include labs.

Cons

• −$249/mo ongoing (month-to-month) is on the high end. Henry Meds is $199/mo for similar compounded care without labs; MEDVi is $179/mo.
• −Cash-pay only — no insurance billing.
• −Cancellation friction is the main 1-star Trustpilot complaint (13% of reviews). Some users report being billed or shipped after they canceled.

Pros

• +Operating since 2022 with a consistent track record — no sudden pricing changes or service disruptions
• +Published average weight loss outcomes: 12-15% body weight at 6 months across their patient base
• +Dedicated care coordinator assigned to each patient — not a rotating pool of providers

Cons

• −$250/mo puts it in the upper-mid range — $90 more than Willow for a similar all-inclusive model
• −No insurance accepted, and no superbill provided for FSA/HSA reimbursement

Pros

• +Specializes in oral compounded semaglutide — the go-to for patients who absolutely won't do injections
• +$199/mo for a fully needle-free GLP-1 program including medication, consultations, and shipping
• +Clear educational content about oral semaglutide absorption and how to maximize effectiveness

Cons

• −Oral compounded semaglutide only — no injectables, no tirzepatide, no brand-name options
• −Oral compounded semaglutide has lower bioavailability than injectable, meaning potentially less weight loss

Pros

• +$179/mo all-inclusive for compounded semaglutide — one of the lowest prices for a full-service program
• +Onboarding takes under 15 minutes with same-day provider review for most applications
• +Published patient reviews averaging 4.5+ stars across third-party platforms

Cons

• −Compounded semaglutide only — no brand-name options and no tirzepatide (compounded or otherwise)
• −No insurance billing, and no superbill provided for out-of-network reimbursement

Pros

• +Same-day physician consults — one of the few platforms offering telehealth appointments the same day you apply
• +80,000+ customer base with 4.9-star Trustpilot rating provides strong social proof of reliability
• +100% money-back guarantee if your consultation determines you don't qualify for GLP-1 treatment

Cons

• −Starting at $289/mo for semaglutide — significantly more expensive than competitors at $99-199/mo
• −$29.99 shipping fee per order — most competitors include free shipping
• −$50 non-refundable cancellation fee after intake approval — penalizes patients who change their mind

Pros

• +Success by Sesame program launched 2026 — $59/mo on a 3/6/12-month plan, bundles labs, unlimited messaging, and provider choice
• +Brand-name cash pricing is competitive — Wegovy pen $199 intro / $349 ongoing, Zepbound vial $299, Wegovy pill $149
• +Foundayo (Lilly's FDA-approved oral GLP-1) available as of April 2026 at $149/mo

Cons

• −Membership model adds complexity — two distinct products (pay-per-visit vs Success membership) can be confusing
• −Success by Sesame requires a 3-month minimum commitment to hit the $59/mo rate
• −Compounded meds are de-emphasized on the current marketing — focus has shifted to FDA-approved brand-name paths

Pros

• +True all-inclusive pricing — $280/mo covers medication, consultations, shipping, and pharmacy fees with no add-ons
• +Clear dose-based pricing published on their site — no surprise cost increases when titrating up
• +Fast pharmacy fulfillment: most orders ship within 48 hours of provider approval

Cons

• −Compounded medications only — cannot prescribe brand-name Wegovy, Zepbound, or Ozempic
• −At $280/mo for compounded-only, it's pricier than competitors like Henry Meds ($199) or TrimRx ($179)

Pros

• +$115/mo starting price with access to both brand-name and compounded — rare at this price point
• +Offers combination therapies (GLP-1 + B12, GLP-1 + NAD+) for patients wanting enhanced protocols
• +Quick asynchronous consultations — most patients approved within 24 hours without video calls

Cons

• −Lighter clinical support than higher-priced platforms — check-ins are patient-initiated, not scheduled
• −No insurance billing and limited customer support hours (business days only, no weekends)

Pros

• +Steep multi-month commitment discounts on compounded sema — $158/mo on 12-month plan ($1,900 upfront) vs $249/mo month-to-month
• +Clinical-service-only path to brand Wegovy and Zepbound at $99/mo — prescription goes to patient's pharmacy (you fill separately using insurance or cash)
• +Same price at all dose levels for compounded — no cost escalation as you titrate up

Cons

• −Brand Wegovy/Zepbound $99/mo is CLINICAL SERVICE ONLY — medication cost is separate (paid at your pharmacy, which can be $1,000+/mo cash without insurance)
• −Best compounded pricing requires 6-12 month prepayment (upfront $1,050-$1,900)
• −90-second assessment quiz suggests convenience over clinical thoroughness compared to competitors with full medical intakes

Pros

• +Simplest all-in pricing: $199/mo flat covering medication, consultation, and free shipping — zero hidden fees
• +48-hour medication shipping — among the fastest fulfillment times in the industry
• +No doctor visit required in most states — maximally convenient for patients who don't want appointments

Cons

• −No video or phone consultation in most states — minimal clinical oversight compared to platforms with regular check-ins
• −No publicly disclosed headquarters, founding date, or pharmacy partners — lack of transparency
• −Limited online review presence makes it difficult to verify patient satisfaction claims

Pros

• +Industry-leading delivery speed — most patients receive medication within 2-3 days of enrollment
• +$149/mo is competitively priced for an all-inclusive compounded program with good support
• +Streamlined onboarding with no video call — approved and shipped faster than most competitors

Cons

• −Compounded semaglutide and tirzepatide only — no brand-name options
• −Newer company (founded 2024) with limited track record and outcome data
• −No insurance billing and no FSA/HSA superbills currently available

Pros

• +Six disclosed clinicians on staff — Daniel Funsch MD, Michael Wasef MD, Takashi Nakamura MD plus three nurse practitioners (Hastings NP, Clements NP, Vergara DNP) — more named providers than most compounded-only platforms publish
• +Month-to-month billing with no minimum commitment — cancel before any renewal date with no early-termination penalty
• +Aggressive promotional pricing on the offer landing — $99-$133/mo compounded semaglutide and $149-$166/mo compounded tirzepatide with a $200 OFF intro discount

Cons

• −Compounded-only — no FDA-approved Wegovy, Zepbound, Ozempic, or Mounjaro through the platform; no Foundayo or oral GLP-1 formats
• −Founding year, headquarters city, and corporate ownership are not publicly disclosed
• −Promotional $99-$133 pricing applies to the introductory offer landing only — standard rate after any qualifying intro period is $174-$283/mo (verify the renewal rate before enrolling)

Pros

• +One of the few compounded providers offering both oral tablets and injectable semaglutide
• +Micro-dosing options available — can start at sub-standard doses for patients concerned about side effects
• +Sleek onboarding experience with clear progress tracking through their patient portal

Cons

• −Compounded medications only — no path to brand-name Wegovy or Zepbound through their platform
• −No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms

Pros

• +Price Lock Guarantee ensures your monthly rate never increases even as your GLP-1 dose escalates — a genuine differentiator
• +Access to 600+ board-certified doctors with unlimited clinician messaging at no additional cost
• +Competitive pricing at $149-$179/mo for compounded semaglutide with free shipping included

Cons

• −Cash-pay only — no insurance accepted, which limits options for patients with GLP-1 coverage
• −Only available in select states — not all 50, and the exact state list isn't published
• −Compounded medications only — no brand-name GLP-1 options available

Pros

• +Two named board-certified doctors (Dr. Michael Wasef MD and Dr. Andrew Sakla DO) — most compounded GLP-1 providers don't publicly name their prescribers.
• +4.6 stars across 1,065 verified Trustpilot reviews — 84% give 5 stars. Top complimented theme: customer service.
• +Cheap if you commit: $146/mo for compounded semaglutide on the 6-month plan.

Cons

• −Compounded-only — no FDA-approved Wegovy, Zepbound, Ozempic, or Mounjaro.
• −The $146/mo price requires a 6-month upfront commitment. Month-to-month is meaningfully more expensive.
• −No live tele-visit option — only async review. Faster, but less depth if you have a complex health history.

Pros

• +Oral dissolving tablets for BOTH semaglutide AND tirzepatide — one of the few platforms with needle-free tirzepatide
• +Free expedited shipping included with all orders
• +24/7 support with unlimited messaging — no per-visit fees for follow-up questions or dose adjustments

Cons

• −Casper, WY registration address and limited independent reviews raise legitimacy questions
• −Brand-name pricing ($499-947/mo) is very high compared to direct manufacturer programs like LillyDirect
• −Company history, founding date, and ownership structure are not publicly disclosed

Pros

• +Both compounded semaglutide AND tirzepatide on a single platform with three commitment tiers (monthly, quarterly, annual)
• +Annual-tier pricing is competitive — $149/mo compounded semaglutide ($1,788/yr) and $229/mo compounded tirzepatide ($2,748/yr) bundle injection supplies, provider oversight, concierge support, and dose adjustments
• +Lab work required upfront — clinically more rigorous than prescribe-and-ship platforms that skip baseline bloodwork

Cons

• −3-month minimum commitment on ALL subscription medications — cancellation only takes effect after the initial 3-month period
• −All prescription sales final, no partial refunds, no mid-cycle credits — strict (though legally typical) for compounded telehealth
• −Compounded only — no FDA-approved Wegovy or Zepbound, no oral semaglutide tablet option

Pros

• +Oral dissolving tablets exclusively — zero injections for any GLP-1 option
• +Publicly traded on NASDAQ (MGRX) — SEC-required financial transparency that private competitors can't match
• +Semaglutide tablet includes Vitamin B6 to help reduce nausea during treatment

Cons

• −$299/mo for oral semaglutide is 2-3x the cost of injectable alternatives at $99-149/mo
• −Early-stage public company with limited revenue — stock performance reflects financial uncertainty
• −Only oral tablet format available — no injectable options if you want higher bioavailability

Pros

• +$130/mo for compounded semaglutide is among the cheapest entries on the market — Sprout Health ($99) and Sesame Care ($99) are lower, but Oak undercuts most mid-tier platforms
• +Compounded tirzepatide at $199/mo is competitively priced for a GLP-1+GIP dual agonist
• +No-subscription model — patients are not auto-charged each month, choose to renew manually. Reduces unwanted recurring charges

Cons

• −Brand-name pricing ($1,200-$1,500/mo) is significantly above market — NovoCare direct pricing for Wegovy is $349/mo, LillyDirect Zepbound $299/mo. Never buy brand-name through Oak
• −No published lab panels, no specialty (obesity medicine) physicians disclosed — clinical depth is shallow
• −'Up to 50% cheaper than competitors' marketing claim is unverified and inconsistent — depends on which competitor and which medication tier

Pros

• +Both oral pill AND injectable GLP-1 options at the same flat $199/mo rate — flexibility to switch formats
• +Named physician leadership (Dr. Ana Lisa Carr MD, Dr. Kelly Tenbrink MD) adds accountability
• +Same price at every dose with no hidden fees — simple, transparent billing

Cons

• −No publicly available company information — founding date, headquarters, and pharmacy partners are undisclosed
• −Very limited independent reviews — difficult to verify patient satisfaction or reliability
• −No insurance acceptance — cash-pay only with no HSA/FSA eligibility disclosed

Pros

• +Compounded GLP-1 available in BOTH injectable AND oral dissolving tablet formats — semaglutide and tirzepatide each in two formats — broader format menu than most compounded-only platforms
• +10% weight-loss money-back guarantee: patients who don't lose at least 10% of baseline weight after 16 weeks of medication adherence may be eligible for refund of up to four months of program fees (verified weight documentation required)
• +Competitive entry pricing — $147/mo compounded semaglutide and $249/mo compounded tirzepatide put Wellorithm near the cheaper end of the compounded market

Cons

• −Founding year, corporate ownership, and named prescribers are NOT publicly disclosed — the only address listed is a German one (Berlin, DE 81566), unusual for a platform serving US patients
• −49 states only — service is unavailable in Louisiana and outside the United States
• −28-day recurring billing cycle with payments non-refundable once processed — strict cancellation policy and no proration for partial months

Pros

• +Active insurance coordination — Found contacts your insurer and reports which GLP-1s are covered, prior auth requirements, and estimated copay
• +10+ medication options including both compounded and brand-name (Wegovy, Zepbound, Wegovy pill) — the widest formulary of any platform
• +Typical insured copay of ~$30/mo for most members — dramatically lower than cash-pay alternatives

Cons

• −Pricing is less transparent than flat-rate competitors — costs vary by insurance status and medication choice
• −The insurance navigation process adds steps and complexity compared to simple cash-pay platforms
• −Compounded medication availability may shift with FDA enforcement changes

Pros

• +Cheap first month — $99 for semaglutide or $149 for tirzepatide. Among the lowest entry prices in the category.
• +Oral tirzepatide gum is rare. Real option for needle-phobic users. (How well it absorbs vs the FDA-approved injection isn't published.)
• +'Embody Flat' plan is $299/mo flat with no surprise increases — predictable if you pick it from the start.

Cons

• −Recurring complaint: people sign up at $149 month 1, get billed $299–$399 in month 2. Embody admits in replies that two plans exist (promo + flat) and the switchover isn't always clear at signup.
• −Trustpilot rating is 3.3 / 5 across 46 reviews — heavily split: 41% love it, 24% give 1 star. Price is the top complaint theme.
• −Embody won't tell you which pharmacy makes the medication — just 'multiple USA certified pharmacies.' This is the norm in the category — most major brands (Embody, Henry, Hims, Yucca, Eden) don't publicly name their pharmacy partners.

Pros

• +Flat $165/mo at all dose levels — price doesn't increase as you titrate up to maintenance doses
• +Semaglutide + B12 formulation helps reduce nausea — the most common GLP-1 side effect
• +100,000+ patient base with 4.9/5 Trustpilot rating from 14,000+ reviews — strong social proof

Cons

• −Only available in 42 states — excluded from 8 states, limiting nationwide access
• −Not BBB accredited, with some documented complaints about delayed medication fulfillment
• −Originally a testosterone replacement therapy platform — GLP-1 is an expansion, not the core focus

Pros

• +No subscription required — order on demand without recurring billing commitments
• +Three formulation options: injectable semaglutide, oral semaglutide tablet, and oral tirzepatide tablet
• +FSA/HSA eligible for those with health savings accounts

Cons

• −Very limited independent reviews and unclear company structure — legitimacy is hard to verify
• −Oral options at $299-399/mo are significantly more expensive than injectable alternatives
• −Not available in all 50 states — varies by provider licensure in your state

Pros

• +2026 Novo Nordisk partnership — FDA-approved Wegovy pen and Wegovy oral pill from $149/mo, one of the lowest brand-name GLP-1 prices on the market
• +Zepbound access via the Lilly/Hims-Hers partnership announced 2026
• +Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance

Cons

• −Membership + medication are billed separately ($39 first month / $149 ongoing membership) — watch the all-in math
• −Generic support experience — large patient volume means less personalized attention
• −Compounded pricing starts at $199/mo but stepped pricing applies at higher doses

Pros

• +Five medication formats — the broadest compounded-GLP-1 menu in DTC telehealth, including the rare oral tirzepatide tablet that almost no competitor offers
• +$199/mo entry price for both injectable and sublingual semaglutide is competitive in the mid-tier compounded segment
• +Fast onboarding: 5–10 minute online questionnaire, physician review in 24–48 hours, medication delivered in 3–7 business days with temperature-controlled shipping

Cons

• −No brand-name FDA-approved options (Wegovy, Zepbound, Ozempic, Mounjaro) — compounded-only model limits patients who want or need an FDA-approved finished product
• −Limited public transparency: founders, executive team, medical director, and specific compounding-pharmacy partners are not named on the public site
• −Cash-pay only — does not bill commercial insurance, Medicare, or Medicaid (HSA/FSA payments accepted)

Pros

• +Dedicated insurance coordinators handle prior authorizations — potentially bringing brand-name GLP-1 costs to $25/mo
• +Multi-month supply options (3, 6, or 12 months) — unique convenience most monthly-shipping competitors can't match
• +Both compounded and brand-name (Wegovy, Zepbound) available with clinician-guided selection

Cons

• −$135 membership fee on top of medication cost makes cash-pay total ~$286/mo for semaglutide — above average
• −Young company (founded 2023) with a relatively small review base — less track record than established platforms
• −Prescription products are non-refundable for any reason once ordered

Pros

• +Microdose compounded tirzepatide at $149/mo — the cheapest microdose tirz on a tracked telehealth platform; full-dose compounded tirzepatide at $179/mo (yearly plan) or $199/mo (3-month plan)
• +Dedicated 'Gala GLP-1 Tracker' on BOTH iOS and Android — first-party in-treatment logging is uncommon among compounded-only platforms
• +OpenLoop-affiliated medical groups + LegitScript verification provide third-party accountability that many compounded-only platforms lack

Cons

• −Brand-name Ozempic pricing ($1,299/mo) is materially above market — NovoCare direct pricing for Wegovy is $349/mo, Hers offers Wegovy at $149/mo via the 2026 Novo Nordisk partnership
• −Tirzepatide-only on the compounded side — compounded semaglutide is NOT offered, narrower medication menu than peers like Maximus, Ro, or Henry Meds
• −Mixed Trustpilot reviews mention dosing inconsistencies and slow customer service responsiveness — verify your specific dose and batch with each refill

Pros

• +Named medical advisor with disclosed credentials — Dr. Mark Rosenberg, M.D., board-certified, 25+ years anti-aging and metabolic-health experience. Most compounded-only platforms in this price tier name no medical director.
• +Competitive entry pricing: $179/mo for compounded semaglutide and $209/mo for compounded tirzepatide undercuts the mid-tier compounded average (~$199/$299) for both formats
• +Multi-month bundles (1, 3, 6, 12 months) with cancel-anytime, no-monthly-membership flexibility — strong fit for users who want to lock in a price without subscription lock-in

Cons

• −Compounded-only — no brand-name FDA-approved Wegovy, Zepbound, Ozempic, Mounjaro, or oral GLP-1 (Foundayo). Patients who want or need an FDA-approved finished product will need a different provider.
• −Pharmacy partner not publicly named — disclosures reference "licensed U.S. pharmacies" generically. Patients who want to verify their compounding pharmacy's 503A licensing or USP-797 accreditation upfront won't find that information on the site.
• −Operating entity is Dynamo Group LLC under a brand license, NOT Bodybuilding.com directly. The "Trusted by millions since 1999" framing leans on the parent brand's retail-supplement history; the GLP-1 program itself is a 2026-launch product without an independent track record.

Pros

• +Lowest entry price in the market — $79.99/mo microdose semaglutide, $99.99/mo 3-month starter pack
• +GLP-1 microdosing available for BMI as low as 22 — the only platform serving patients below standard obesity criteria
• +Nausea-reducing formula with added glycine and B12 to ease GLP-1 side effects

Cons

• −Deceptive pricing structure — $99.99/mo is intro only, standard dosing is $299.99/mo with separate $28-35 consultation fees and $199-349/yr lab costs
• −Refuses to disclose compounding pharmacy partners — a transparency red flag for a healthcare platform
• −Prices increase as dose escalates on bulk plans — unpredictable total cost over time